Is Scpharmaceuticals Stock a Good Investment?
Scpharmaceuticals Investment Advice | SCPH |
- Examine Scpharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Scpharmaceuticals' leadership team and their track record. Good management can help Scpharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Scpharmaceuticals' business and its evolving consumer preferences.
- Compare Scpharmaceuticals' performance and market position to its competitors. Analyze how Scpharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Scpharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Scpharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Scpharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Scpharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Scpharmaceuticals Stock
Researching Scpharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 87.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.95. Scpharmaceuticals had not issued any dividends in recent years.
To determine if Scpharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Scpharmaceuticals' research are outlined below:
| Scpharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 13.59 M. Net Loss for the year was (54.81 M) with profit before overhead, payroll, taxes, and interest of 21.11 M. | |
| Scpharmaceuticals currently holds about 55.85 M in cash with (59.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Scpharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Market Sentiment Around Loss-Making scPharmaceuticals Inc. |
Scpharmaceuticals Quarterly Cash And Short Term Investments |
|
Scpharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Scpharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Scpharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Scpharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Scpharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.4 | -0.44 | -0.04 | 10 | ||
2021-08-11 | 2021-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2021-05-12 | 2021-03-31 | -0.3 | -0.26 | 0.04 | 13 | ||
2023-11-08 | 2023-09-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2022-08-09 | 2022-06-30 | -0.3 | -0.35 | -0.05 | 16 | ||
2020-11-16 | 2020-09-30 | -0.38 | -0.33 | 0.05 | 13 | ||
2023-05-10 | 2023-03-31 | -0.36 | -0.3 | 0.06 | 16 | ||
2020-08-13 | 2020-06-30 | -0.42 | -0.36 | 0.06 | 14 |
Know Scpharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Scpharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Scpharmaceuticals backward and forwards among themselves. Scpharmaceuticals' institutional investor refers to the entity that pools money to purchase Scpharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kingdon Capital Management Llc | 2024-09-30 | 800 K | Stonepine Capital Management Llc | 2024-09-30 | 778.9 K | Awm Investment Company Inc | 2024-09-30 | 764.9 K | Nantahala Capital Management, Llc | 2024-09-30 | 750 K | State Street Corp | 2024-09-30 | 682.1 K | Geode Capital Management, Llc | 2024-09-30 | 643.3 K | Tejara Capital Ltd | 2024-12-31 | 612.9 K | Citadel Advisors Llc | 2024-09-30 | 526 K | Velan Capital Investment Management Lp | 2024-09-30 | 517.7 K | Orbimed Advisors, Llc | 2024-09-30 | 6.1 M | Rubric Capital Management Lp | 2024-09-30 | 4.8 M |
Scpharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 184.15 M.Market Cap |
|
Scpharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (1.69) | (1.61) |
Determining Scpharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Scpharmaceuticals is a good buy. For example, gross profit margin measures Scpharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Scpharmaceuticals' profitability and make more informed investment decisions.
Evaluate Scpharmaceuticals' management efficiency
Scpharmaceuticals has return on total asset (ROA) of (0.3444) % which means that it has lost $0.3444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0065) %, meaning that it created substantial loss on money invested by shareholders. Scpharmaceuticals' management efficiency ratios could be used to measure how well Scpharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.55. The Scpharmaceuticals' current Return On Capital Employed is estimated to increase to -0.74. As of now, Scpharmaceuticals' Non Currrent Assets Other are increasing as compared to previous years. The Scpharmaceuticals' current Other Current Assets is estimated to increase to about 4.3 M, while Total Assets are projected to decrease to under 90.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.11 | 1.06 | |
| Tangible Book Value Per Share | 1.11 | 1.06 | |
| Enterprise Value Over EBITDA | (4.59) | (4.82) | |
| Price Book Value Ratio | 5.84 | 6.13 | |
| Enterprise Value Multiple | (4.59) | (4.82) | |
| Price Fair Value | 5.84 | 6.13 | |
| Enterprise Value | 211.4 M | 222 M |
Effective leadership at Scpharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.103 |
Basic technical analysis of Scpharmaceuticals Stock
As of the 17th of February 2025, Scpharmaceuticals has the Coefficient Of Variation of (2,551), risk adjusted performance of (0.02), and Variance of 12.69. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Scpharmaceuticals, as well as the relationship between them.Scpharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Scpharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Scpharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Scpharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scpharmaceuticals' Outstanding Corporate Bonds
Scpharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Scpharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Scpharmaceuticals bonds can be classified according to their maturity, which is the date when Scpharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Scpharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Scpharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 2.78 | |||
| Coefficient Of Variation | (2,551) | |||
| Standard Deviation | 3.56 | |||
| Variance | 12.69 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.16) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 14.54 | |||
| Value At Risk | (4.55) | |||
| Potential Upside | 5.07 | |||
| Skewness | (0.84) | |||
| Kurtosis | 2.22 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 2.78 | |||
| Coefficient Of Variation | (2,551) | |||
| Standard Deviation | 3.56 | |||
| Variance | 12.69 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.16) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 14.54 | |||
| Value At Risk | (4.55) | |||
| Potential Upside | 5.07 | |||
| Skewness | (0.84) | |||
| Kurtosis | 2.22 |
Consider Scpharmaceuticals' intraday indicators
Scpharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Scpharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Scpharmaceuticals Corporate Filings
F4 | 12th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of January 2025 Other Reports | ViewVerify | |
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of December 2024 Other Reports | ViewVerify |
Scpharmaceuticals Stock media impact
Far too much social signal, news, headlines, and media speculation about Scpharmaceuticals that are available to investors today. That information is available publicly through Scpharmaceuticals media outlets and privately through word of mouth or via Scpharmaceuticals internal channels. However, regardless of the origin, that massive amount of Scpharmaceuticals data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Scpharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Scpharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Scpharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Scpharmaceuticals alpha.
Scpharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Scpharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Scpharmaceuticals Corporate Management
| John PharmD | Senior Affairs | Profile | |
| Rachael Nokes | Principal Accounting Officer | Profile | |
| Katherine Taudvin | Director Relations | Profile | |
| Michael Hassman | Senior Operations | Profile | |
| Steve Parsons | Senior Commercial | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 1.641 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Scpharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.